Brain Tumour Foundation of Canada

Brain Tumour Foundation of Canada

July 14, 2010 10:13 ET

Brain Cancer Research Receives $250,000 Boost

Seven Grants and One Fellowship Awarded By Brain Tumour Foundation of Canada

Attention: City Editor, Health/Medical Editor, Lifestyle Editor, News Editor, Science Editor LONDON, ONTARIO, PRESS RELEASE--(Marketwire - July 14, 2010) - Research into the cause of and cure for brain tumours got a $250,000 boost with the announcement of seven new grants and a fellowship awarded by Brain Tumour Foundation of Canada.

This year marks the first awarding of the William Donald Nash Brain Tumour Research Fellowship, with $100,000 going to Dr. Tommy Alain at McGill University. Through the Fellowship, Dr. Alain will spend the next two years investigating more effective treatments by combining novel therapies and monitoring the outcomes.

The annual grants-in-aid program received 18 applications this year and the seven Canadian researchers were awarded more than $150,000 for projects focused on causation, diagnosis and treatment.

"The prospect for all of the research that will be conducted as a result of these funds is very exciting," says Dr. Joseph Megyesi, Chair of Brain Tumour Foundation of Canada. "Our vision is to find a cure for brain tumours and to improve the quality of life for those affected and we believe this research will be another step on this journey."

Fellowship Research Summary:
Dr. Tommy Alain of McGill University in Montreal Quebec, will investigate two promising brain tumour therapies which have been found to work together to eliminate brain tumours and significantly prolong the survival of animal models of brain cancers. The aim is to further the understanding of the possibility of using these therapies in future clinical trials to enhance the outcomes of brain tumour patients.

Research Project Award Summaries:

1. Dr. Caroline Chung, at Princess Margaret Hospital in Toronto, Ontario will evaluate a variety of biomarkers to guide individualized therapy for patients with brain metastasis.

2. Dr. Kim Edelstein, at Princess Margaret Hospital in Toronto, Ontario will explore the developmental impact of both brain tumours and radiation therapy on adolescent and young adult brain tumour survivors.

3. Dr. Barbara Fisher of the University of Western Ontario in London, Ontario will explore how to precisely identify the point in time when brain tumours start to recur in order to offer additional treatment at the optimal time.

4. Dr. Marshall W. Pitz, at Cancer Care Manitoba in Winnipeg will explore the molecular markers of Gliobalstoma Multiforme (GBM) brain tumours which will enable the identification of key therapeutic targets and assist in personalized care for those diagnosed with GBMs.

5. Dr. Arjun Sahgal, at University Toronto, Sunnybrook Health Sciences Centre and Princess Margaret Hospital, University Health Network will explore the optimal timing and type of treatment for low grade Astrocytoma brain tumours as well as the impact of treatment on health care resources and quality of life.

6. Dr. Nahum Sonenberg, at McGill University in Montreal, Quebec, will examine the role of proteins in both the development of brain tumours and possible treatments.

7. Dr. Slav Yartsev, of London Regional Cancer Program, London Health Sciences Centre in London, Ontario will monitor brain tumours' response to radiation treatment through a new type of CT test.
/For further information: Please visit our website at www.braintumour.ca./ IN: EDUCATION, HEALTH, SOCIAL, OTHER

Contact Information

  • Paul Mitchell, Community Relations Officer, Brain Tumour Foundation of Canada
    Primary Phone: 519-642-7755 ext. 232
    Toll-Free: 800-265-5106
    E-mail: pmitchell@braintumour.ca